leishmania

SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).

Leishmania peptide 183 is an antigen.

Compound 17k, also known as Antileishmanial agent-30, effectively inhibits Leishmania with an IC50 of 0.2 μM for L. donovani. It exhibits a CC50 of >100 μM and an SI of >500, indicating significant selectivity and potency.

Antileishmanial agent-8 (compound 18) exhibits potent and selective activity against Leishmania donovani (L. donovani) with an IC50 of 5.64 μM and relatively low cytotoxicity in L-6 cells with an IC50 of 73.9 μM [1].

Antileishmanial agent-3 (Compound 13) effectively inhibits the growth of *Leishmania major* [1].

Antileishmanial agent-9 (compound 16c) exhibits potent and selective activity against Leishmania donovani (L. donovani) with an IC50 value of 4.01 μM, while demonstrating relatively low cytotoxicity in L-6 cells with an IC50 value of 40.1 μM [1].

Antileishmanial agent-7 (compound 23) exhibits potent antileishmanial activity against Leishmania donovani with an IC50 of 6.89 μM and against L-6 with an IC50 of 259 μM [1].

Antileishmanial agent-12 (compound 5a) is a potent antileishmanial agent with antibacterial activity against Leishmania braziliensis (IC50: 14.9 μM), Leishmania infantum (IC50: 21.3 μM), and T. cruzi (IC50: 9.3 μM), demonstrating significant antiprotozoal effects.

Antileishmanial agent-6 is a potent anti-leishmanial agent with anti-leishmanial activity (IC50: 0.54 μM) and cytotoxicity (IC50: 10.2 μM) against Leishmania donovani and L-6.

Antileishmanial agent-11 is a potent antileishmanial agent that acts on Leishmania brazilensis (IC50: 28.3 μM), Leishmania infantum (IC50: 24.8 μM) and T. cruzi (IC50: 13.0 μM) with outstanding antiprotozoal effect.

Antileishmanial agent-13, a quinoline-isatin hybrid, functions as an antileishmanial agent targeting the L. Major Leishmania strain through an anti-folate mechanism. This compound exhibits potent inhibition of both the promastigote and amastigote forms, boasting IC50 values of 0.604 μM and 0.508 μM, respectively.

Antileishmanial agent-14, a sulfuretin analog, exhibits potential activity against Leishmania donovani promastigotes (IC 50 = 4.1 μM) and inhibits infection by L. donovani amastigotes (IC 50 = 11.1 μM) [1].

Antileishmanial agent-16 (compound 14c), an anti-Leishmania agent, exhibits potent activity against Leishmania major promastigotes (IC50 = 0.59 µM) and amastigotes (IC50 = 0.81 µM), while maintaining a favorable safety profile in mammalian cells (VERO cells) [1].

Antileishmanial agent-23 (compound G1 9), a potent and selective trypanothione reductase (TR) inhibitor, exhibits an IC50 of 2.24 ± 0.52 μM and effectively inhibits the growth of Leishmania, Trypanosoma cruzi, and Trypanosoma brucei [1].

Compound F27 (Antileishmanial agent-19) is an antileishmanial compound effective against L. donovani promastigotes, demonstrating an IC50 of 3.39 μM. It functions by inhibiting the Leishmania prolyl-tRNA synthetase and disrupting the host PI3K Akt CREB axis-mediated IL-10 secretion. Additionally, Compound F27 promotes autophagy-mediated apoptosis in L. donovani promastigotes and has been shown to reduce parasite burden in L.d-infected animals [1].

Antileishmanial agent-20 exhibits selectivity against the Leishmania parasite, with IC50 values of 2.8 μM for L. infantum and 0.2 μM for L. braziliensis. It is a potential research tool for studying these parasites [1].

Antileishmanial agent-21 (compound 4e) functions as an inhibitor of Leishmania pteridine reductase 1 (Lm-PTR1), employing an anti-folate mechanism. Its antileishmanial effects can be negated by folic acid and leucovorin. Additionally, it demonstrates inhibitory activity against the chloroquine-resistant Plasmodium falciparum strain RKL9, with an IC50 ranging from 0.0198 to 0.096 μM [1].

Antileishmanial agent-22 (compound 15b) acts as an antiparasitic and antibacterial agent, demonstrating activity against Leishmania (IC50 = 0.408 μM), malaria, and tuberculosis. It functions via an antifolate mechanism, inhibiting folic and folinic acids with 88% and 94% efficacy at 100 μM. The compound inhibits P. berghei by 96.67% in vivo in vitro at 48.4 μM kg day and 0.038 μM (IC50), and it inhibits M. tuberculosis with an MIC of 28.44 μM [1].

Antileishmanial agent-31 (Compound p1) is a pyrazole derivative exhibiting antileishmanial activity with an IC50 of 35.53 μg mL. Furthermore, Antileishmanial agent-31 demonstrates high stability and is applicable in studies focused on leishmaniasis treatment.

Antileishmanial agent-33 (4e) is a hybrid compound of grandisin and machilin G, demonstrating moderate activity against promastigotes with an IC50 of 38.1 μM. In studies of cutaneous leishmaniasis (CL), Antileishmanial agent-33 (4e) has shown potential as an antileishmanial agent.

Antileishmanial agent-1 demonstrates activity against both L. amazonensis promastigotes (IC 50 = 15.52 μM) and intracellular amastigotes (IC 50 = 4.10 μM).

Antileishmanial agent-4, a ribonucleoside analogue, functions as an antileishmanial agent [1].

Antileishmanial agent-4 is a ribonucleoside analogue with potent activity against L. infantum and T. cruzi, exhibiting EC50 values of 0.68 μM and 0.83 μM, respectively [1].

Antileishmanial agent-10 (Compound 7h) is an antiprotozoal agent effective against leishmaniasis.